CVAC Stock Analysis: Buy, Sell, or Hold?
CVAC - CureVac N.V. Ordinary Shares
$4.66
-0.01 (-0.21%)
βΌ
5d:
+8.37%
30d:
-9.95%
90d:
-14.5%
BUY
MODERATE Confidence
Analysis Updated: Jan 5, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When CVAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
π‘ BUY OPPORTUNITY: CVAC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
π‘ BUY OPPORTUNITY: CVAC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CVAC is currently trading at $4.66, which is considered fair based on recent price action.
Technical Outlook: Technically, CVAC is in a strong downtrend. The price is approaching resistance at $4.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.38 (+15.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CVAC is in a strong downtrend. The price is approaching resistance at $4.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.38 (+15.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
58/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
66.8%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: Trading below Wall St target ($5.38)
Support & Resistance Levels
Support Level
$4.00
Resistance Level
$4.68
Current Trend
Strong Downtrend
Technical data as of
Jan 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.38
Wall Street Target
$5.38
(+15.6%)
Revenue Growth (YoY)
-89.0%
Earnings Growth (YoY)
24.0%
Profit Margin
182.1%
Share & Embed Analysis
Last updated: April 29, 2026 1:38 PM ET
Data refreshes hourly during market hours. Next update: 2:38 PM
Data refreshes hourly during market hours. Next update: 2:38 PM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CVAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals β¦ |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 57 HOLD |